Soliqua

Active Ingredient(s): Insulin Glargine + Lixisenatide
FDA Approved: * November 21, 2016
Pharm Company: * SANOFI AVENTIS US
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Soliqua Overview

Lixisenatide (trade name Lyxumia in the Europe and Adlyxin in the U.S.) is a once-daily injectable GLP-1 receptor agonist for the treatment of diabetes type II. Contents 1 Medical use 2 Adverse effects 3 Mechanism of action 4 Chemistry 5 History 6 References Medical use Lixisenatide is used as adjunct to diet and exercise to treat diabetes type II.[1] In Europe, its use is limited to complementing insulin therapy.[2] It is provided in an autoinjector containing fourteen doses and ...

Read more Soliqua Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lixisenatide

Recent Soliqua Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Insulin Glargine + Lixisenatide
  • Injection: 100units + 33mcg
  • Solution: 300 Units/3ml + 99mcg/3ml (100 Units/ml + 33mcg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (6 results)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 26 September 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.